{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:23:23Z","timestamp":1787570603898,"version":"build-2736575974"},"reference-count":54,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Tumor-infiltrating lymphocyte (TIL) therapy is the first adoptive cellular therapy approved to treat solid tumors and has demonstrated durable responses in advanced melanoma. However, its clinical implementation is limited by the need for tumor harvesting, manufacturing delays, and lymphodepleting conditioning. These logistic challenges are also opportunities for physicians and scientists to consider combining TIL therapy with radiation therapy (RT), a modality with well-established roles in cancer care. RT exerts both immunostimulatory and immunosuppressive effects, influencing antigen presentation and T-cell trafficking while also contributing to lymphocyte depletion in a dose- and context-dependent manner. These properties provide a strong biologic rationale for integration with TIL therapy but also introduce important uncertainties. Preclinical studies suggest RT can enhance TIL expansion and function, while early clinical experience supports the feasibility of RT delivery before and after TIL therapy in selected scenarios. However, prospective clinical data remain limited, and key questions regarding optimal timing, dose, and target selection are unresolved. In this review, we propose a workflow-based framework for combining RT with TIL therapy across pre-harvest, bridging, peri-infusion, and post-infusion settings. RT is a promising partner to TIL therapy, but prospective studies will ultimately be needed to define how best to integrate RT in order to translate biologic synergy into consistent clinical benefit.<\/jats:p>","DOI":"10.3390\/curroncol33090498","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:07:53Z","timestamp":1787566073000},"page":"498","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combining Radiation Therapy and Tumor-Infiltrating Lymphocyte Therapy: Biological Rationale, Clinical Synergies, and Future Directions"],"prefix":"10.3390","volume":"33","author":[{"given":"Sean","family":"Maroongroge","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"McGee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2544-5191","authenticated-orcid":false,"given":"Kelly","family":"Mahuron","sequence":"additional","affiliation":[{"name":"Department of Surgery, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savita","family":"Dandapani","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1020-0845","authenticated-orcid":false,"given":"Terence M.","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myo","family":"Htut","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2668-3415","authenticated-orcid":false,"given":"Colton J.","family":"Ladbury","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3501-5790","authenticated-orcid":false,"given":"Yufei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arya","family":"Amini","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e008735","DOI":"10.1136\/jitc-2023-008735","article-title":"Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy","volume":"12","author":"Hamid","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s10238-025-01574-6","article-title":"Tumor infiltration therapy: From FDA approval to next-generation approaches","volume":"25","author":"Shaik","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/PPO.0000000000000608","article-title":"Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy","volume":"28","author":"Mullinax","year":"2022","journal-title":"Cancer J."},{"key":"ref_5","first-page":"38","article-title":"The T-cell Growth Factor Cocktail IL-2\/IL-15\/IL-21 Enhances Expansion and Effector Function of Tumor-Infiltrating T cells in a Novel Process Developed by Iovance","volume":"3","year":"2017","journal-title":"Lung"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1200\/JCO-25-00765","article-title":"Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study","volume":"43","author":"Medina","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_11","unstructured":"U.S. Food and Drug Administration (2026, March 22). FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"TPS9607","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9607","article-title":"A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma","volume":"41","author":"Olson","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"104671","DOI":"10.1016\/j.critrevonc.2025.104671","article-title":"Outcomes of tumor-infiltrating lymphocyte therapy in solid tumours\u2014A systematic review and meta analysis","volume":"209","author":"Mony","year":"2025","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ijrobp.2025.06.3856","article-title":"Local Single-Dose Radiation Improves Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes","volume":"123","author":"Obertopp","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1038\/s41467-019-11906-2","article-title":"Tumor-reprogrammed resident T cells resist radiation to control tumors","volume":"10","author":"Arina","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e138740","DOI":"10.1172\/JCI138740","article-title":"Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control","volume":"131","author":"Lhuillier","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.1016\/j.ijrobp.2025.06.2099","article-title":"Nascent Clinical Experience with Radiotherapeutic Management of Melanoma Brain Metastases in Patients Treated with Tumor-Infiltrating Lymphocyte (TIL) Therapy","volume":"123","author":"Choudhury","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1182\/bloodadvances.2025015855","article-title":"Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: An ILROG multicenter study","volume":"9","author":"Plastaras","year":"2025","journal-title":"Blood Adv."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ladbury, C., Dandapani, S., Hao, C., Fabros, M., Amini, A., Sampath, S., Glaser, S., Sokolov, K., Yeh, J., and Baird, J.H. (2023). Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed\/Refractory Large B Cell Lymphoma. Cancers, 15.","DOI":"10.3390\/cancers15061747"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Manzar, G.S., Pinnix, C.C., Dudzinski, S.O., Marqueen, K.E., Cha, E.E., Nasr, L.F., Yoder, A.K., Rooney, M.K., Strati, P., and Ahmed, S. (2025). Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1517348"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1084\/jem.171.1.249","article-title":"Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action","volume":"171","author":"Cameron","year":"1990","journal-title":"J. Exp. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00002371-199211000-00007","article-title":"A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy","volume":"12","author":"Lange","year":"1992","journal-title":"J. Immunother."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Puebla-Osorio, N., Fowlkes, N.W., Barsoumian, H.B., Xega, K., Srivastava, G., Kettlun-Leyton, C., Nizzero, S., Voss, T., Riad, T.S., and Wong, C. (2024). Enhanced tumor control and survival in preclinical models with adoptive cell therapy preceded by low-dose radiotherapy. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1407143"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","article-title":"Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e14527","DOI":"10.1200\/JCO.2023.41.16_suppl.e14527","article-title":"Tolerability and response of palliative radiotherapy in patients receiving tumor-infiltrating lymphocyte therapy","volume":"41","author":"Rogers","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djs629","article-title":"Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift","volume":"105","author":"Formenti","year":"2013","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2217\/fon-2020-0994","article-title":"The Abscopal Effect of Radiation Therapy","volume":"17","author":"Craig","year":"2021","journal-title":"Future Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","article-title":"Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated","volume":"58","author":"Demaria","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ctrv.2005.03.004","article-title":"The controversial abscopal effect","volume":"31","author":"Kaminski","year":"2005","journal-title":"Cancer Treat. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41568-025-00903-x","article-title":"Radiation as an immune modulator: Mechanisms and implications for combination with immunotherapy","volume":"26","author":"Darragh","year":"2026","journal-title":"Nat. Rev. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"100808","DOI":"10.1016\/j.neo.2022.100808","article-title":"The paradox of radiation and T cells in tumors","volume":"31","author":"Gough","year":"2022","journal-title":"Neoplasia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.semradonc.2019.12.004","article-title":"Effects of Radiation on the Tumor Microenvironment","volume":"30","author":"Monjazeb","year":"2020","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2021.0168","article-title":"Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review","volume":"7","author":"Hauth","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Paganetti, H. (2023). A review on lymphocyte radiosensitivity and its impact on radiotherapy. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1201500"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ijrobp.2024.04.065","article-title":"Longitudinal Assessment of Tumor-Infiltrating Lymphocytes in Primary Breast Cancer Following Neoadjuvant Radiation Therapy","volume":"120","author":"Yoneyama","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1158\/2326-6066.CIR-17-0040","article-title":"Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment","volume":"5","author":"Muroyama","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1016\/S1470-2045(19)30401-2","article-title":"Rational combinations of immunotherapy with radiotherapy in ovarian cancer","volume":"20","author":"Herrera","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.radonc.2021.01.034","article-title":"Risk and impact of radiation related lymphopenia in lung cancer: A systematic review and meta-analysis","volume":"157","author":"Upadhyay","year":"2021","journal-title":"Radiother. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1038\/s41467-022-34676-w","article-title":"Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors","volume":"13","author":"Darragh","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_45","unstructured":"Khaddour, K. (2026, July 01). A Feasibility Study of Tumor Infiltrating Lymphocytes in Cutaneous Squamous Cell Carcinoma and Merkel Cell Carcinoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07288073."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ijrobp.2025.08.058","article-title":"Tumor-Infiltrating Lymphocytes and Preoperative Partial Breast Irradiation in Early-Stage Breast Cancer: Insights From the Prospective PAPBI Cohort","volume":"124","author":"Gunster","year":"2026","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijrobp.2024.08.008","article-title":"PRECISE: Preoperative Radiation Therapy to Elicit Critical Immune Stimulating Effects\u2014A Phase 2 Clinical Trial","volume":"121","author":"Shaitelman","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-25-2743","article-title":"Combinatorial Delivery of Low-Dose Radiotherapy and Immunotherapy to Patients with Immune-Excluded Tumors Enhances CD8+ T-cell Functionality","volume":"32","author":"Rayroux","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_49","unstructured":"NeogenTC (2026, July 01). Phase I Clinical Trial to Evaluate the Safety and Tolerability of NEOG-100 in Patients with Advanced Breast Cancer and Lung Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06107894."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/s41416-026-03350-z","article-title":"Tumour-infiltrating lymphocyte therapy in melanoma: Ready for prime time?","volume":"134","author":"Woodford","year":"2026","journal-title":"Br. J. Cancer"},{"key":"ref_51","unstructured":"(2026, April 25). Pilot Study to Evaluate the Feasibility, Safety, and Efficacy of Adoptive Transfer of Autologous Tumor-Infiltrating T Lymphocytes Selected to Specifically Recognize the Tumor (NeoTIL) in Patients with Advanced Solid Tumors. Available online: https:\/\/www.humanforschung-schweiz.ch\/en\/trial-search\/study-detail\/53326\/translate\/en."},{"key":"ref_52","unstructured":"Coukos, G. (2026, July 01). Phase Ib Study to Assess the Feasibility and Safety of Adoptive Transfer of Autologous Tumor-Infiltrating Lymphocytes in Advanced Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04643574."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Wong, J.Y.C., Liu, A., Han, C., Dandapani, S., Schultheiss, T., Palmer, J., Yang, D., Somlo, G., Salhotra, A., and Hui, S. (2022). Total marrow irradiation (TMI): Addressing an unmet need in hematopoietic cell transplantation\u2014A single institution experience review. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1003908"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1186\/s12967-024-05826-z","article-title":"Clinical trial landscape for TIL therapy: Emerging insights and future directions in oncology","volume":"22","author":"Hong","year":"2024","journal-title":"J. Transl. Med."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/498\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:45:40Z","timestamp":1787568340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":54,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["curroncol33090498"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33090498","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}